Expanding into Biopharmaceuticals Vamsi Chavakula Sungshik Kim David Liu Radhika Marathe
2
Executive Summary
The pharmaceutical industry is in total more profitable than any other industry in
the United States. The highly lucrative payoffs are countered by heavy risks associated
with drug research and development, which may take as many as ten years in a product
life cycle. In addition, companies must deal with securing FDA approval for their
products, which may provide yet another barrier to producing a pharmaceutical product.
Pfizer is currently the largest pharmaceutical company in this industry, accruing
revenues of $51.3 billion in 2006. Known for its innovative medicines, Pfizer has brought
a number of successful drugs to the market, including Viagra, Celebrex, and Lipitor,
currently the top selling drug in the world. However, it faces a myriad of competitors in
the industry with over 200 major companies vying for the production of the next so-
called “blockbuster drug.” In addition, the market game is changing as new technologies
such as biopharmaceuticals threaten to displace traditional medications. In light of this
competition, we recommend that Pfizer take the following actions:
o expand its efforts to lobby the government to protect its interests, including
stricter regulation of new companies to discourage entry into the pharmaceutical
industry and the biotech pipeline, extension of patents on existing exclusive
drugs, and stricter enforcement of patent infringements.
o extend its resources in biotech by focusing on excelling in an ophthalmology
niche and then using this as a focal point to expand into related fields in biotech
through its existing synergies and efficient sales and marketing arm.
3
Table of Contents
Introduction
4
Biotech as the Future for Pharmacy
6
Porter’s Six Forces Analysis
8
Strengths, Weaknesses, and Opportunities
13
Threats and Competition
15
Suggested Strategies
18
Conclusion
24
Appendix
25
References
28
4
Introduction
Pfizer is the largest pharmaceutical company in the world – it was named by Fortune
Magazine as the fifth-best “wealth-creator” in America. Currently Pfizer places primary
focus on the development of chemical compounds into therapeutic drugs and health
products for humans and animals. It can divert revenue from these two divisions, as well
as from the smaller consumer health care division (with products such as Schick razors,
Trident gum, and over-the-counter medications like Sudafed) into any of the other
divisions for growth and investment.
Pfizer has grown over the years to an extent through internal development and
licensing, but primarily through acquisitions and mergers to solidify its position in a
given concentration or begin expansion into a new therapeutic area - for example, in 2003
Pfizer merged with Pharmacia to broaden Pfizer’s product line, increase revenue, and
make research and development more efficient. The new company then works to trim the
fat by eliminating redundant practices and creating synergies between the existing
operations of subsidiaries. Through this expansion, the company now offers
pharmaceuticals in over 40 different categories of diseases/conditions. The company has
remained successful by allocating a vast amount of resources (over $5 billion a year) into
its research and development unit, more than any of its competitors. In addition, the
company has spent on the same order of revenue on marketing of drugs, causing some of
their products (such as Lipitor, Claritin, and Viagra) to become household names.
With its merger with Pharmacia in 2003, Pfizer acquired its first biotech facility in St.
Louis. The company has a relatively small pipeline for these biotech drugs – in contrast
to its role as a leading company in the pharmaceutical business, Pfizer as a late entrant
5
into biotech is still far behind prominent competitors such as Roche, Johnson & Johnson,
and Amgen, the industry leader. Biotech promises to be the future of medicinal therapy
for the world (see next section) and will likely become an increasingly important facet to
success in the pharmaceutical industry. Pfizer is far behind in the game – what can the
company do in order to aggressively move into this emerging field?
6
Biotech as the Future for Pharmacy
Currently the entire pharmaceutical industry seems to be favoring the shift from
ordinary organic molecule treatments to biotech solutions.
“The basic science underlining all biopharmaceutical drugs is that every living
cell in the human body contains DNA (deoxyribonucleic acid) and contained within them
are genes. Cells are able to perform their functions because of the instructions encoded
within the genes… These genes are then isolated and duplicated on a large scale to
produce the desired protein, which is then extracted, purified and used for the production
of the biopharmaceutical or biotech drugs, as they have come to be known.” (A.N.
Aditya, Technical Insights, Frost & Sullivan).
One of the primary reasons for the shift in research paradigm is that current drugs
are proving to have limitations both in efficiency and effectiveness. One of the issues
confronting organic molecule treatments is the problem of drug delivery. Physiologically,
it is very difficult to ensure that an organic chemical drug acts on only a desired location
in the body, because it can never be determined how effectively the drug will reach its
target organs. This is the issue of drug delivery, and current research for solutions to this
dilemma are being sought after in the biotech world because it is believed that by
utilizing protein therapies, the body’s natural transport and recognition systems can be
harnessed to ensure that the drug acts on only the appropriate targets, and that significant
amounts of the drug are able to reach the target organ. Through the use of biologically
synthesized molecules, such as hormones and proteins that are naturally produced by the
body, it is hoped that greater drug efficacy is achieved. In addition, most organic
7
chemicals work in the body by acting as homologs (having similar structural properties)
to certain compounds in the body. Biotech seeks to manufacture the desired biological
molecules exactly and introduce them as the treatment substance. Examples such as
artificial insulin and lab synthesized clotting factors serve as examples as to how
conditions that were untreatable by conventional treatments are now being unlocked.
At this time, it seems that there are three areas of focus by the pharmaceutical
industry in the biotech market. The first are of research is novel drug delivery systems, as
mentioned above. Nanoparticles and various drug introduction systems are being studied
in order to more effectively deliver treatment to damaged targets, while preventing the
actions of the drug anywhere else. Hence, this field strives to improve the specificity of
drugs and thereby reduced adverse side effects.
Another field of study utilizes modified proteins to accurately detect contaminants
in small fluid samples. Such products have applications not only in human fluids such as
blood, but can be utilized to analyze environmental samples such as water contamination
levels, or gasoline purity levels.
Finally, biotech firms are concentrating on medical devices such as heart assist
devices, and other electronic devices that will improve the functioning of impaired
organs. This field is still very young, and significant improvements are yet to be seen.
Overall, the field of biotechnology offers faster and more efficient solutions to the
pharmaceutical industry than were previously possible with conventional chemical
molecule treatment with the benefit of reduced side effects. It would be unwise for Pfizer
not to consider expansion into this new and developing field.
8
Porter’s Five (Six) Forces Analysis
Buyer Bargaining Power
o Little bargaining power for individuals who end up consuming the drugs because
there are few alternatives for any specific drug and the individuals are not
associated in any way (to form any kind of union, etc.), which may gain some
bargaining power.
o Pharmacies also have little bargaining power because they merely sell what the
individuals demand (especially when the product is recommended by a doctor).
o However, HMO’s and other health insurance agencies have significant amounts
of bargaining power because they can choose not to subsidize certain drugs
(deeming them unnecessary) or they can subsidize certain drugs more than others.
Often a HMO will have a partnership with certain companies to favor that
company’s drugs.
Supplier Bargaining Power
o Chemical plants and material suppliers such as Aldrich have very little bargaining
power. Prior to the expiration of a patent, the cost of actually producing a brand
name drug is very low compared to the retail price of the drug, as seen in the
many-fold drop in price when a comparable generic is released. Even when a
generic drug is released, there are still a number of suppliers to choose from; the
resources required to produce the pharmaceuticals are not restricted to a limited
set of suppliers.
9
o The pharmaceutical companies for security, integration, and quality control
reasons however often own these suppliers.
o Individual scientists that work for a pharmaceutical company such as Pfizer have
very little bargaining power since they sign away the intellectual rights to any
discovered product while working for the company.
o However, if a group of scientists independently, either in an institution or small
company, make a discovery, that institution or company can have a potentially
large amount of bargaining power for that discovery.
o The institution will often license the right to the discovery while small companies
often merge with the buyer.
Rivalry
o For a drug that is within its period of exclusivity, the company that distributes it
can exercise monopoly pricing since it is the only drug available to treat a certain
condition.
o This patent tends to reduce competition between pharmaceutical industries during
this phase. However, companies can try to subvert the patent law by developing a
similar drug to treat the health condition that goes about the problem in a different
manner; this will undercut the monopoly and increase the rivalry between the
companies.
o Several companies have prescription drugs in a specific category such as second-
generation painkillers or prescription stomach acid reducing drugs – these
products can usually be substituted with one another, increasing the rivalry in this
market.
10
o Price competition is not particularly strong in this industry due to pressure from
insurance companies and government regulation. Price cutting will not increase
revenues or units sold significantly because each drug possesses a unique set of
attributes, i.e. targets and side effects. In general, such drugs are prescribed by
physicians who will not factor price into their decision of which drug a patient
should receive. In other words, Pfizer should not expect a great increase in
revenue or units sold due to a price cut – considering the rival response, Pfizer
should not consider price slashing as a viable strategy for future growth.
o In addition, a number of companies can have the same type of drugs in
development. For highly publicized types of drugs, such as those designed to cure
AIDS, this increases the rivalry, as it soon becomes a race to whoever can patent
the drug first.
New Entrants/Barriers to Entry
o There are a number of barriers to entry, which is what contributes to making the
pharmaceutical industry and the biotech pipeline very profitable.
o However, these high profits are what drive entry, which is made all the more
attractive if there is a good product.
o With a specific type of drug already on the market, a competitor will need time to
research and develop its own version of that drug and patent any technological
advances that arise during this phase. It also requires a talented group of lawyers
to create the patents and be prepared to litigate in order to enforce them.
o In addition, the competitor will need to prove to doctors, hospitals, and health care
professionals that the product is as good, if not better, than the original product.
11
o With regards to a new type of drug, a company first needs a marketable product,
which means either a successful and large research and development team, or
quite a bit of serendipity.
o A large amount of capital ($800 million on average to bring a drug into the
market) and time are necessary to take the drug from its conceptual stage to the
final production and distribution. This includes animal and human testing, passing
government regulations (FDA approval), and convincing people that the product
is both effective and necessary.
o In addition, existing pharmaceutical companies can lobby the government against
new entrants to make it more difficult to gain access to the drug market. Pfizer has
one of the largest lobbying arms in the industry today and should be able to
exercise this muscle further to keep entrants out.
o A new entrant lacks the strong brand name and reputation, as well as the
necessary connections that could help to facilitate this process and reduce cost.
They also lack the economies of scale and distribution networks already in place
for existing players in the industry.
o Again, the company will require a group of lawyers to protect this novel drug
from encroachment.
Substitutes
o When a drug is in its period of exclusivity, there aren’t (by definition) many
viable substitutes.
12
o On occasion, a similar drug will be released within a few years, but often the only
substitutes are alternative medicinal therapies (such as standard Asian therapies
such as Ayurveda and acupuncture), surgery, or other medical procedures.
o Once the period of exclusivity has ended, there are a variety of substitutes as
generic drugs come into the picture. Prolonging this exclusivity period then is a
desirable strategy to keep a pharmaceutical company profitable.
Complements
o For a specific drug, the main complement is whatever the drug is designed to
treat, prevent, or cure, whether it is a disease, an illness, an injury, or a side effect
caused by another drug.
o If the health issue is capable of mutation, the complements can include related
drugs since an increase in a drug’s usage could lead to immunity to that particular
drug, resulting in the increased usage of a related drug (e.g. the high turnaround
time associated with AIDS drugs).
o In general, complements also include well-educated doctors, favorable
government policies (thus the necessity for strong lobbying), and insurance
companies including Medicare.
13
SWOT Analysis of Pfizer
Strengths
o As the current leader in the pharmaceutical industry, Pfizer has a number of
advantages. It has a strong and large sales force that is capable of effectively
marketing their products.
o The company also has a strong reputation in the industry, which confers a three-
fold advantage – a) it eases the approval process by the FDA, b) makes the drug
more likely to be recommended by doctors and approved by insurance carriers,
and c) gives Pfizer an edge when trying to convince others to license new
products to it.
o By holding the top position in the industry, Pfizer has the most fluid capital to
reinvest into research (about $5 billion per year), take risks in high return type
products, or outbid rivals on a crucial product.
o In addition, Pfizer already has large research facilities and production capabilities,
while also spending the most in research and development of new products.
Weaknesses
o As the leading pharmaceutical company in the industry, Pfizer also has the largest
overhead cost and must spend a sizeable fraction of its revenues filing and
defending lawsuits on its existing products.
o Although Pfizer has a wide variety of drugs, it is dependent on a handful of drugs
for the majority of its revenues. When patents on these drugs expire, Pfizer will
14
face severe losses in profit unless the company can time the release of a new
product when the patent on an older product runs out. For example Pfizer will
lose exclusive rights for Lipitor production in 2010, which currently accounts for
about 25% of its revenues worldwide. This product timing is largely a function of
research and government approval, which makes it difficult for the company to
plan ahead. To take measures into its own hands, Pfizer must have a strategy for
the development of products and maintain healthy relations with the government.
o As a late entrant into the biopharmaceuticals market, Pfizer enjoys very little
market share and revenue compared to what it generates in traditional
pharmaceutical drugs. Without strategic action, Pfizer risks losing ground on
competitors of comparable size with a mature biopharma portfolio.
o Insurance companies can pressure the company to lower prices on their products
or risk being denied coverage, and therefore use by the final consumer.
Opportunities
o As the baby boomer generation grows older, this graying population will require
an assortment of prescription medicines and services as the average life
expectancy increases due to the improvement in healthcare. By catering to this
demographic, Pfizer can lock in a number of these customers, who will be around
for a while and will be dependent on these therapeutic drugs.
o Pfizer also has an opportunity to expand globally and enter new markets such as
India, China, and South Korea that have a large population base that is expected
to get wealthier and older over the next few years. At present, many of Pfizer’s
drugs are priced outside of the range of the average person in these countries. But
15
with their continued economic success, it is highly possible that all three will
become major markets for pharmaceutical drugs.
o In addition, there are a number of possible alternatives open to Pfizer with regards
to recent scientific discovers, such as gene therapy and stem cell research. Both of
these technologies are still in the development stage and will likely face stiff
cultural opposition, but both represent a possible “next” market.
Threats and Competition
o Pfizer faces a number of threats to its premier market position. High gross profits
across the industry attract entry, which, in principle, is feasible for an entrant with
a novel idea or application.
o Each new entrant into the industry could potentially become a long-term
competitor – for instance, new startups that do not want to merge with a larger
company may grow to competitive size. As an example, Amgen began its entry
into the industry in 1985 and has since become a major rival to Pfizer.
o There is also a long-term threat from generic drugs produced by such companies
as Teva and Barr that creates competition when Pfizer’s drugs come off their
period of exclusivity.
o Established companies can displace Pfizer as market leader in this volatile market.
Below are the strategic positions of Johnson & Johnson and GlaxoSmithKline, the
two next highest revenue-grossing pharmaceutical companies in the industry.
16
Johnson & Johnson
In contrast to Pfizer, Johnson & Johnson, the closest competitor in terms of
revenue, is a multidivisional firm that focuses not only on pharmaceutical drugs and
consumer products, but also places a much higher emphasis on medical devices. It is
independent of any one drug, drug category, or consumer product as it can funnel profits
from any one division into another. The company also has a strong reputation, and most
worrisome for Pfizer, large amounts of operating profits that can be used to diversify or
counter strategic repositioning by Pfizer. Johnson & Johnson is less broad than Pfizer
with regard to product development, instead focusing on the development of drugs in
twelve key categories (as opposed to the nineteen offered by Pfizer) such as Alzheimer’s
disease, oncology, and urology. Inside of this therapeutic area focus, Johnson & Johnson
makes strategic acquisitions to complement existing products and research in these areas,
create synergies, and boost revenue. In addition, Johnson & Johnson expanded into
biopharma through the acquisition of successful firms in the sister industry earlier than
Pfizer, giving it a head start in carving out a niche and taking market share. Although it
may be better known for its consumer products, J&J is in a strong position as the number
two pharmaceutical company and can take Pfizer’s place should it falter.
GlaxoSmithKline
GlaxoSmithKline plc (GSK) is the third largest pharmaceutical company in the
world – in addition to producing prescription medicines and consumer health care
products like Pfizer and Johnson & Johnson, GSK differentiates itself as a large producer
of vaccines and antibiotics. In 2000, GSK accounted for over a quarter of all vaccine
sales. It has a very large sales force (40,000+), which is capable of ensuring the
17
distribution of GSK products around the globe. The GSK growth strategy has involved
internal development and extension of key products such as Advair for the treatment of
asthma, in-licensing for organic growth with companies such as Merck, and increasing its
pipeline of vaccines (over 20 in development) for a number of conditions. Two other
positions that GSK has taken is aggressive development of HIV/AIDS as well as
investment into genetics and gene sequencing. GSK is also already a player in the biotech
market.
18
Suggested Strategies
Aggressive Lobbying
An effective practice that pharmaceutical companies often employ is lobbying the
government for favorable treatment. Pfizer has spent over $20 million in lobbying
expenses in the past decade in order to protect its interests; these include extension of
patents on existing drugs, tax breaks, protection, and enforcement of its patent laws.
Recipients of these funds have included such politicians as Senator Richard Gephardt, Kit
Bond, and Joseph Lieberman. These grateful politicians are then in place to help the
company once elected to office.
On a number of occasions, Congress has deliberated on the ability of
pharmaceutical companies to extend patents on exclusive drugs, thus denying the
company the ability to enjoy longer periods of high profits with the associated high price
to consumers. Pfizer stands to lose a substantial amount of revenue should measures like
these pass through the House and Senate.
Pfizer should then continue to place heavy emphasis on lobbying politicians by
increasing contributions (within the legal limit) towards causes that would subvert bills
such as these. In addition to the promotion of the enforcement of patent law, Pfizer
should also lobby to make it harder for new entrants to make it into the industry and the
biotech pipeline. This could be through more extensive testing, proof of quality, and
safety for products in the FDA approval process for new companies and stricter
requirements for the assembly of new production facilities. This applies to foreign
competitors as well; it could include strict inspection of facilities abroad and heavy
19
regulation on the packaging and importation of goods. In the past, Pfizer has pressed
politicians for trade sanctions against companies that import cheap generic copies of their
patented drugs – Pfizer should continue this exercise as well as petition the World Health
Organization to uphold the company’s patent law worldwide.
There should be little to no opposition to this strategy from Pfizer’s main
competitors. Since these practices will tend to benefit the entire industry as a whole in
barring access to the market to new players, it will ensure that any competition for market
share will be between entrenched companies.
Pfizer should however refrain from lobbying against existing competitors in the
industry. For instance, if Pfizer were to lobby for stricter government regulation in a
therapeutic focus in which it has little interest, this could antagonize other companies for
which that focus is their specialization (for example, GlaxoSmithKline would be
aggravated if Pfizer were to lobby for greater regulation of vaccines). Pfizer is not the
only company in pharmaceuticals that spends a large amount of operating profit on
lobbying the United States government; Johnson & Johnson, Merck, and Roche are not
far behind. The incited rival response could be detrimental to Pfizer; the other companies
could lobby the government for tighter control of FDA regulation in the cardiovascular
market. This could potentially escalate into a conflict that is harmful for all players
involved. Knowing this, Pfizer should not be the first to throw the stone; rather, by
working to keep new competitors out of the market, it can obtain greater market share
from existing competitors by other means.
20
Specialization
Although Pfizer is the leader in pharmaceuticals, since it was not one of the first
firms to enter the biopharmaceutical industry, its competitors have gained incumbent
advantages and larger market shares. To carve out a niche in the biotech pipeline, Pfizer
should focus on an area that does not have high-density competition. At this point, most
of the major areas or research such as protein, hormone, enzyme, and blood factor
creation for systems such as cardiovascular, central nervous and etc already have a lot of
firms vying for the lion’s share of the market.
Pfizer should start out in an area with relatively less competition – we have
identified ophthalmology as a potential market for the company to start its expansion into
biotech. This is for four reasons:
1) None of the top competitors in the biotech market, including Amgen and
Johnson & Johnson have entered this sector of the market.
2) Pfizer already has a pharmaceutical research and development unit in
ophthalmology. Incorporating biotech into this existing research unit will help ease the
company’s entry into the market. Further, Pfizer entered a licensing agreement with
Quark Biotech, an innovative biopharmaceutical developing treatments for diseases of
the kidney and lungs, as well as fibrotic and ischemic diseases of the eye. With their
expertise, Pfizer should be able to quickly gain experience in this niche.
3) For the aging baby boomer generation, retention of sight is of particularly high
importance. By expanding early into ophthalmology and capturing a growing proportion
of potential buyers, Pfizer can lock in a sales blocks for years to come.
4) On the other hand, ophthalmology is not a sufficiently attractive sector of the
biotech market for competitors to enter given that Pfizer has made it the company’s
21
primary focus. While the sector can be profitable, it will not be able to match the margins
for more profitable areas of biotech such as cardiovascular or cancer treatment. If Pfizer
can develop quality treatments that give value to their customer base, it will be difficult
for another company to undercut the incumbent. Given the smaller profit margins, it may
not be profitable for another company to do so. In short, ophthalmology is an attractive
market for one player, but not sufficiently large for two.
Diversification
Pfizer should then begin its expansion conquest of the biotech industry in
ophthalmology. Here they can gain experience in how the industry operates (move right
along the experience curve) and adapt to the different requirements for success as
compared to the traditional pharmaceutical drug industry that it has dominated. During
this time, Pfizer should plan cost-efficient strategies for production and make use of its
existing distribution network to develop economies of scale for their products. As Pfizer
expands in this market sector, Pfizer should take care to impose heavy quality testing on
all of products coming out of the biotech pipeline. This will be to establish a reputation as
a safe manufacturer of biotech products, a distinction that will carry over into other
sectors of the biotech market.
Once Pfizer has solidified its position in the ophthalmology department, it can
begin to look into related fields to enter. By diversifying their biotech product portfolio,
the company can continue its strategy to carve out a place for itself in the biotech
industry, which according to our eight to ten year projected strategy will have huge
payoffs for the company in the years to come.
22
Pfizer would have a three-fold cost sharing advantage when moving into these
related fields. First, the manufacturing facilities will share a number of related multi-
purpose technologies that can be used for the simultaneous production of
biopharmaceutical products. This will place downward pressure on the costs of expansion
since Pfizer already has the production capabilities to handle the expanded drug portfolio.
There will also be a set of educated specialists who can be shared across various areas of
the industry and add their area of expertise to any project that they work on. These cross-
fertilizations will allow for the spread of working ideas (such as a particularly effective
paradigm, i.e. an efficient protein structure, etc.) and efficient practices across the new
frontier of research for Pfizer. Finally, Pfizer has a strong advantage with its large sales
and marketing arm – by announcing its entry into new fields in biotech and flooding the
public with information on their products, Pfizer can make their products known more
effectively than competitors, thus making it more likely that their product will be the one
prescribed.
With its history of acquisitions, Pfizer should also consider acquiring a few
companies that show promising research in the desired field. In this way Pfizer can gain
patents, licenses, and specialized personnel to excel in these new fields, while those
companies gain Pfizer’s expertise in sales and marketing and existing distribution
networks. At this time, Pfizer should also make use of the aggressive lobbying strategy
cited above to make it difficult for additional entrants to make it in the industry while
establishing its leadership. Ultimately, Pfizer should look to the production of proteins to
complement their cardiovascular drugs, at present the most profitable and fastest growing
sector of the pharmaceutical industry.
23
Since biotech is a broad and growing market with many existing companies,
Pfizer’s competitors will have a difficult time blocking Pfizer’s movement into this
sector. As discussed earlier, cutting prices is not an effective strategy for competition in
this industry. Also, other companies cannot try to dislodge the Pfizer giant by appealing
to the government since Pfizer can lobby in retaliation. What leading competitors like
Johnson & Johnson and Amgen can do is try and lock in a given constituency with their
existing drug/treatment/method rather than trying the new Pfizer version by pushing their
product with their sales team. They can also drive up acquisition costs or purchase the
desired biotech companies themselves in order to block Pfizer’s entry. However, they
cannot keep Pfizer out of a sector of the market completely, and will most likely
accelerate production or increase the allocation of resources into the sector in order to
beat Pfizer to the next product. As long as Pfizer utilizes its unique strengths and
synergies, it will have a strategic advantage that cannot be easily reproduced by its
competitors.
24
Conclusion
Pfizer is standing at the crossroads with its current position. If biotech really is the
future of the industry then the company risks being left behind as competitors extend
their biopharmaceutical portfolios. In order to enjoy the types of revenue and market
share that it currently holds in the next eight to ten years, the company necessarily must
take action to secure its future position.
As such, we have identified ophtamology as a potential cornerstone from which
the company can expand into the biotech market. From this focal point, the company can
use its existing size to spill over into related markets. However, with sizeable competition
in these sectors, it will be important for Pfizer to execute this strategy effectively through
efficient production, strong sales and marketing, and savvy acquisition. Although it may
not be able to completely displace the current biopharmaceutical leaders, Pfizer can use
these strategies to at the very least better its current position in this market. Since success
in biotech implies success in the pharmaceutical drug industry, Pfizer can maintain a
strong role in the production of tomorrow’s treatments for the next generation.
25
Appendix
Table 1: Top 10 Global Pharmaceutical Companies
2005 US Revenue (USD billions)
Pfizer Inc 51,300
Johnson & Johnson 50,514
GlaxoSmithKline Plc 39,421
Sanofi-Aventis Group 33,946
Novartis AG 32,212
Roche Holding AG 28,505
AstraZeneca PLC 13,950
Abbott Laboratories 13,338
Merck & Co., Inc 22,012
Bristol-Myers Squibb Company 19,207
Source: Datamonitor
Table 2: Total Contributions to federal Parties by Pfizer &
Pharmacia prior to their merger in 2003 (Source: opensecrets.org)
Pfizer
Cycle Total
From
Individuals
From
PACs
Soft Money
Contributions
Percentage to
Democrats
Percentage to
Republicans
1990 $150,050 $10,250 $139,800 $0 54% 46%
1992 $304,757 $32,180 $190,600 $81,977 39% 61%
1994 $546,903 $41,676 $261,692 $243,535 36% 64%
1996 $888,116 $83,300 $289,100 $515,716 22% 78%
1998 $1,144,310 $85,580 $311,680 $747,050 20% 80%
2000 $2,492,166 $370,379 $562,970 $1,558,817 15% 85%
2002 $1,280,404 $45,140 $396,000 $839,264 21% 78%
TOTAL $6,806,706 $668,505 $2,151,842 $3,986,359 22% 78%
26
Pharmacia
Cycle Total
From
Individuals From PACs
Soft Money
Contributions
Percentage to
Democrats
Percentage to
Republicans
1990 $248,995 $19,385 $229,610 $0 46% 53%
1992 $494,318 $91,475 $269,405 $133,438 43% 56%
1994 $456,714 $90,629 $259,185 $106,900 48% 51%
1996 $536,171 $123,046 $219,625 $193,500 31% 68%
1998 $297,070 $121,725 $150,345 $25,000 35% 65%
2000 $1,257,470 $204,145 $168,650 $884,675 19% 81%
2002 $945,919 $86,019 $100,953 $758,947 23% 77%
Total $4,236,657 $736,424 $1,397,773 $2,102,460 30% 70%
Figure 1: Annual lobbying by Pfizer (1999 – 2006)
Source: opensecrets.org
27
Figure 2: Proportion for Key Pharmaceutical Firms in Biopharma and
traditional Pharmaceutical drugs
Source: pubs.acs.org
28
References
http://www.pfizer.com
http://www.media.pfizer.com/pfizer/download/investors/presentations/shedlarz_presentat
ion_012207.pdf
http://www.datamonitor.com
http://www.wikipedia.com
http://www.pmi.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-10-
2006/0004279298&EDATE=
http://www.jnj.com
http://www.gsk.com
http://www.corporatewatch.org.uk/?lid=329
http://www.opensecrets.org
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-22-
2001/0001433051&EDATE=
http://pubs.acs.org/cen/coverstory/8219/8219biopharma.html
http://www.amgen.com/science/pipe.jsp
http://www.jnj.com/innovations/biotech/partner_biotech_2002.pdf
http://www.accessexcellence.org/RC/VL/GG/biotechnology.html
http://www.pharmabioingredients.com/articles/2006/03/biopharmaceuticals-what-the-
future-holds
http://www.business.com
McAfee, R. Preston. Personal interview. 28 Feb. 2007.